179 results about "Xanthine oxidase" patented technology

The invention discloses a xanthine oxidase inhibitory peptide with a kidney improving function and application thereof, and belongs to the technical field of biological medicines.The xanthine oxidase inhibitory peptide is screened out by conducting enzymolysis, separation and purification on litopenaeus vannamei processing by-products and utilizing a molecular docking technology, the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Leu-Gly-Pro-Pro-Pro, and the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Leu-Gly-Pro-Pro-Pro. And the half inhibition concentration of the polypeptide is 2.356 + / -0.2448 mM. The xanthine oxidase inhibitory peptide is proved to have an improvement effect on hyperuricemia mice, the improvement effect is mainly characterized by reducing the content of serum uric acid, creatinine and urea nitrogen of the hyperuricemia mice, inhibiting the activity of xanthine oxidase (XOD) in serum and livers of the mice, inhibiting synthesis of uric acid and improving kidney injury of the mice, and Toxinpred prediction shows that the xanthine oxidase inhibitory peptide has the effect of inhibiting the activity of xanthine oxidase (XOD) in the serum and livers of the mice. The xanthine oxidase inhibitory peptide is free of toxic and side effects, so that the xanthine oxidase inhibitory peptide has a wide application prospect in preparation of food or drugs for improving renal functions.

The invention discloses a xanthine oxidase inhibitory peptide with uric acid reducing activity and application thereof, and belongs to the technical field of biological medicines.The xanthine oxidase inhibitory peptide is obtained by conducting enzymolysis, separation and purification on processing byproducts such as litopenaeus vannamei heads and shells with xanthine oxidase inhibitory activity. The xanthine oxidase inhibitory peptide is screened by using a molecular docking technology, and the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Pro-Val-Pro-Pro-Pro. The xanthine oxidase inhibitory peptide has an XOD (X-Oxidase) half inhibitory concentration of 3.181 + / -0.1786 mM. The invention further proves that the xanthine oxidase inhibitory peptide has a certain improvement effect on hyperuricemia mice, and the xanthine oxidase inhibitory peptide mainly has the effects of reducing the content of serum uric acid, creatinine and urea nitrogen of the hyperuricemia mice, inhibiting the activity of xanthine oxidase (XOD) in serum and liver of the mice, inhibiting synthesis of uric acid and improving kidney injury of the mice, and the xanthine oxidase inhibitory peptide has a certain improvement effect on the hyperuricemia mice through Toxinpred prediction. The xanthine oxidase inhibitory peptide uric acid reducing peptide is free of toxic and side effects and has a wide market application prospect.

The invention belongs to the technical field of medicines, and particularly relates to application of eupatorium chinense extract in preparation of a medicine for treating gout. Researches show that the eupatorium chinense extract and the active components thereof have good biological activity and can inhibit the activity of xanthine oxidase (XOD). Molecular docking experiments also show that the eupatorium chinense extract and xanthine oxidase have good binding energy. Further research finds that the eupatorium chinense extract can reduce the levels of uric acid and creatinine in serum in a hyperuricemia mouse body, and has good uric acid reducing activity. In the field of treatment of hyperuricemia and gout, many traditional medicines have many adverse reactions. Compared with the prior art, the eupatorium chinense serving as a traditional Chinese medicine provides a safe and effective natural medicine for treating hyperuricemia and gout or gout complications due to the efficient uric acid reducing effect of the eupatorium chinense.

The invention relates to the field of preparation and application of biological peptides, in particular to a swelling hippocampal peptide and application thereof in preparation of uric acid reducing and gout resisting products. The amino acid sequence is shown as SEQ ID NO.1. The uric acid reducing effect of the compound is proved through in-vitro xanthine oxidase (XOD) and adenosine deaminase (ADA) inhibition experiments and cell experiments; on the basis, the uric acid reducing and gout resisting activity of the peptide sequence is further verified by means of a hyperuricemia animal model. The achievement provides a solid theoretical support for high-value development and utilization of the hippocampus japonicus and research and development of uric acid reducing and gout resisting related products.

The invention relates to an application of sea cucumber intestine polysaccharide in preparation of uric acid lowering drugs. The preparation method of the sea cucumber intestine polysaccharide comprises the following steps: performing enzymolysis treatment on sea cucumber intestines by using papain, performing enzyme deactivation, performing centrifugation, and taking supernate; and carrying out graded alcohol precipitation on the supernate, centrifuging, taking precipitate, deproteinizing and freeze-drying. The preparation method is simple, green and environment-friendly. The sea cucumber intestine polysaccharide prepared by the method can effectively inhibit the activity of xanthine oxidase; the sea cucumber intestine polysaccharide has no toxic effect on HK-2 cells. The compound has a uric acid reducing effect on HK-2 hyperuricemia cells.

The invention discloses camel milk polypeptide with xanthine oxidase inhibitory activity and application thereof.The camel milk polypeptide is prepared by taking fresh camel milk as a raw material, conducting low-temperature centrifugation to remove fat, conducting triple enzymolysis through papain, pepsin and trypsin to obtain enzymatic hydrolysate, enabling the enzymatic hydrolysate to pass through an ultrafiltration membrane (the molecular weight cutoff is 10 kDa) to obtain filtrate, and conducting freeze-drying to obtain the camel milk polypeptide. The compound has xanthine oxidase inhibitory activity. The invention also discloses a small molecule polypeptide with xanthine oxidase inhibitory activity. The filtered solution is screened and combined with polypeptides by adopting a xanthine oxidase affinity ultrafiltration method, the activity of the polypeptides is verified through molecular docking and in-vitro enzyme inhibition, four small-molecule polypeptides with xanthine oxidase inhibitory activity are obtained, the sequence of the small-molecule polypeptides is shown as any one of SEQ ID NO.1-4, and the small-molecule polypeptides can be used for preparing drugs with the effect of inhibiting the uric acid level.

The invention relates to the technical field of medicines, in particular to application of an active ingredient xanthohumol (XAN) derived from a traditional Chinese medicine humulus lupulus in preparation of medicines for reducing uric acid and resisting gout, and the xanthohumol (XAN) can be prepared into various oral preparations, injection preparations and external preparations with the assistance of pharmaceutically acceptable auxiliary materials and has good development and application prospects. The inventor finds that the xanthohumol has relatively strong effects of reducing blood uric acid, resisting inflammation, resisting bone damage and the like, and the mechanism of the effect of reducing the blood uric acid is that the activity of xanthine oxidase is inhibited so as to reduce the generation of uric acid, and the renal function of an organism is improved so as to enhance uric acid excretion; according to the anti-inflammatory effect, the inflammatory reaction is relieved mainly by down-regulating the levels of inflammatory factors such as IL-1beta, IL-6, TNF alpha and PEG2; the mechanism for resisting gout bone damage is realized through the fact that RANKL / OPG / RANK signal pathway participates in bone metabolism regulation.

The invention relates to euphausia superba peptide with uric acid reducing activity and application thereof. The euphausia superba peptide is a short peptide obtained by extraction, enzymolysis, separation and purification from degreased euphausia superba powder, and the amino acid sequence of the euphausia superba peptide is Ser-Ala-Gly-Lys-Thr. Researches show that the peptide can reduce the generation of uric acid by inhibiting the activity of xanthine oxidase and promote the excretion of uric acid. In-vitro cell experiments prove that under the concentration of 10 mu M, the inhibition rate of the peptide on xanthine oxidase reaches 23.1%; animal experiments show that the blood uric acid level of mice in a high-dose group (50mg / kg) is reduced by about 40% compared with that in a model group. The invention also develops a health-care beverage and a medicinal preparation which take the peptide as an active component, and provides a new choice for preventing and treating hyperuricemia and gout.

According to the preparation method disclosed by the invention, the whole fruit juice of the lonicera caerulea (which retains fruit residues) is fermented by virtue of the plant lactobacillus KLDS1.0391, KLDS1.0320 or KLDS1.0368, so that the xanthine oxidase (XO) inhibition activity is remarkably improved. After fermentation, the XO inhibition rate is increased to 48-50.87% (the content of unfermented juice is 31.21%), the total phenol content is increased by 15-24.3%, and the contents of main XO inhibitors in the lonicera caerulea: cyanidin-3-O-glucoside (IC50 = 115.28 [mu] M), cyanidin-3, 5-diglucoside (IC50 = 116.34 [mu] M), peonidin-3-glucoside (IC50 = 105.34 [mu] M), quercetin (IC50 = 88.75 [mu] M), catechin (IC50 = 110 [mu] M) and caffeoylquinic acid (IC50 = 250.35 [mu] M) are remarkably increased. Wherein the quercetin content is increased by 73.8% at most (KLDS1.0320 strain fermentation is performed for 24 hours), and the XO inhibition rate is increased from 31.21% to 50.87%. Technical support is provided for development of a natural XO inhibitor and a functional fermented beverage, so that a new thought is provided for functional fermented juice with lonicera caerulea as a key component.

The invention discloses a siraitia grosvenorii instant coffee beverage assisting in reducing uric acid and a preparation method thereof, and belongs to the technical field of food based on the theory of homology of medicine and food. The coffee beverage is composed of instant coffee powder, a compound sweetening agent, coconut milk powder, milk powder and composite herbal powder in a specific proportion. The compound herbal powder is composed of poria cocos, peach kernels, dried tangerine or orange peel and momordica grosvenori which are selected from a medicinal and edible substance catalog. The herbal active ingredients and a coffee system are deeply fused by optimizing an extraction process, the dual regulation effects of inhibiting xanthine oxidase and promoting uric acid excretion are synergistically exerted, and the technical contradiction that common caffeine possibly affects uric acid excretion is effectively solved. The zebra fish in-vivo experiment proves that the level of uric acid can be remarkably reduced (Plt: 0.001), the improvement rate is as high as 17.63%, and a safe and effective daily diet intervention scheme is provided for people with hyperuricemia while the coffee flavor and convenience are provided.

The invention belongs to the technical field of microbial fermentation, and discloses lactobacillus mucilaginosus and application thereof in preparation of a uric acid reducing preparation. The survival rate of the fermented lactobacillus mucus in simulated gastric juice with the pH value of 2.0 for 3 hours is greater than 92%, the survival rate in simulated intestinal juice environment containing 0.5% of cholate is greater than 86%, and the viability of the fermented lactobacillus mucus is obviously higher than that of a conventional strain; and the tea has the effects of reducing uric acid, resisting oxidation and inhibiting pathogenic bacteria. The xanthine oxidase inhibition rate of the natural medicinal and edible compound potion obtained by mixing and co-fermenting the strain and existing bacterial powder is greater than 77% (45% or more higher than that of an unfermented group), and the oxidation resistance after fermentation can be improved by 50% at the same time. The beverage is suitable for being drunk as a daily functional food for a long time, and provides a natural and healthy collaborative diet relieving scheme for patients with hyperuricemia and gout.

The invention discloses a uric acid reducing composition and a preparation method and application of plant extracts of the uric acid reducing composition, and belongs to the technical field of traditional Chinese medicine formulas and preparation. The uric acid reducing composition is prepared from the following raw materials in parts by mass: 3 to 27 parts of corn stigma, 3 to 27 parts of pericarpium citri reticulatae and 3 to 27 parts of white kidney beans. The preparation method of the plant extract comprises the following steps: pretreating the raw materials, extracting effective components, compounding according to different proportions, evaluating the in-vitro xanthine oxidase inhibition effect by using the plant extract, determining the formula compatibility of the raw materials according to quantitative pharmacology, and further determining the formula compatibility of the uric acid reducing composition. The corn stigma is treated by adopting a steam wall breaking technology, so that the extraction rate of effective components of the corn stigma is remarkably improved, and the uric acid reducing effect of the product is enhanced; the uric acid reducing food prepared on the basis of the uric acid reducing composition is safe, free of side effects and suitable for being eaten by people with high uric acid for a long time.

The invention provides peony polypeptide for reducing uric acid as well as a preparation method and application thereof, and belongs to the technical field of biology. The preparation method comprises the following steps: soaking and cleaning peony seed meal with ethanol, centrifuging at 3000-500r for 30-50min, taking a first precipitate, drying the first precipitate, adding water, adjusting the pH value to 9-10, carrying out alkali extraction at 45-55 DEG C for 70-80min, taking supernate, adjusting the pH value to an isoelectric point, and taking a second precipitate; the second precipitate is subjected to enzymolysis for 2-8 h under the conditions that the temperature is 20-80 DEG C, the pH is 5-9, and the protease addition amount is 1500-9000 U / g, and the peony polypeptide capable of reducing uric acid is obtained. The compound has inhibitory activity on xanthine oxidase, and the active components of the compound have stability and functionality by adopting ultrafiltration grading and simulated digestion model exploration.

The invention discloses a uric acid reducing polypeptide, the polypeptide is derived from a peptide fragment, the'bindingerge 'value of the peptide fragment in molecular docking with xanthine oxidase is less than-1.5 kcal / mol, and the peptide fragment, in molecular docking with the xanthine oxidase, of the polypeptide is derived from a Peptide Ranker biological activity score gt; and 0.7 of a polypeptide. The uric acid reducing polypeptide is obtained by screening natto powder subjected to pepsin enzymolysis, natto powder enzymatic hydrolysate obtained through enzymolysis has the activity of inhibiting xanthine oxidase, the screened uric acid reducing polypeptide can be developed into a uric acid reducing medicine, and active ingredients are added into functional food and health food, so that the uric acid reducing polypeptide has a good application prospect. Good market prospects are realized in medicine and food industries.

The invention discloses a preparation method and application of hydrolyzed casein peptide capable of reducing uric acid and facilitating gout attack prevention and gout symptom improvement, belongs to the technical field of biology, and has a wide application prospect. The casein hydrolysate peptide prepared by the method disclosed by the invention can effectively reduce uric acid, and is beneficial to preventing gout attack and improving gout symptoms by the following ways: 1, inhibiting the activity of xanthine oxidase (UA enzyme), and reducing the generation of uric acid; 2, metal ions such as Ca < 2 + > and Na < + > are complexed to prevent generation of urate crystals, so that gout attack can be prevented; 3, the microenvironment of an articular cavity is improved, urate crystals are dissolved, and the gout symptom can be improved; and 4, liver and kidney inflammation caused by high uric acid is relieved.

The invention discloses application of polydatin in preparation of a medicine for relieving hepatotoxicity caused by zearalenone, and belongs to the technical field of biological medicine. The invention reveals that polydatin inhibits hepatotoxicity caused by zearalenone through targeted xanthine oxidase for the first time, so that the toxicity of zearalenone to an organism is relieved. Polydatin can be directly combined with xanthine oxidase to inhibit the catalytic activity of xanthine oxidase, so that the oxidative stress injury of the liver after ZEA exposure is reduced, meanwhile, the content of malondialdehyde (MDA) in the liver can be remarkably reduced, the activity of superoxide dismutase (SOD) is improved, the liver oxidation-antioxidant balance is recovered, and liver cells are protected from oxidative injury of ZEA. The invention provides a new scientific basis and development direction for application of polydatin in the fields of mycotoxin detoxification, oxidation resistance, liver protection and the like.

The invention relates to a food-borne melanin-containing uric acid-reducing food composition which is prepared by mixing 2-10 parts by weight of celery seed extract, 1-6 parts by weight of food-borne melanin and 0-5 parts by weight of astragalus extract, plays a role in reducing uric acid by inhibiting the activity of xanthine oxidase, and has a better effect of treating hyperuricemia and / or gout. The liver and kidney injury caused by hyperuricemia can be improved, the toxic and side effects are low, and the food can be eaten for a long time.

The application discloses a composition for protecting liver and strengthening kidney and reducing uric acid, which is made of the following raw material components: Anoectochilus roxburghii, dried tangerine or orange peel, chicory, gardenia, turmeric, Hovenia dulcis Thunb, Cistanche deserticola Y.C.Ma, Rehmannia glutinosa, potassium citrate, sodium citrate and goose myo-peptide. The composition combines the immortal concept of TCM (Traditional Chinese Medicine) "treating disease from the root" and the uric acid control method of modern nutritional medicine as an organic whole, and achieves multiple effects of protecting liver and strengthening kidney, mutual benefit of yin and yang and reducing uric acid through multiple action targets. Animal experiment results show that the composition can effectively reduce the activities of transaminase ALT and AST, relieve liver damage, reduce serum creatinine level and improve urea ammonia excretion rate, improve kidney function, inhibit the activities of xanthine oxidase and adenosine dehydrogenase and reduce uric acid level. The composition is safe and has no toxic side effects, is suitable for people with insufficient liver and kidney functions and hyperuricemia and has a wide application prospect.

The invention discloses a recombinant strain for efficiently expressing xanthine oxidase as well as preparation and application of the recombinant strain, and belongs to the technical field of enzyme engineering. According to the recombinant strain, four kinds of recombinant Pseudomonas putida strains are designed, and the strains can be used for efficiently expressing xanthine oxidase. The recombinant strain has the advantages of high expression quantity, simple affinity purification process flow, high purification yield and low production cost, and the recombinant xanthine oxidase has the specific activity similar to that of xanthine oxidase sold in the market at present and is suitable for various applications. The recombinant strain can realize high-efficiency expression of xanthine oxidase, and high-efficiency expression of xanthine oxidase is realized in P.putida through a gene recombination technology; the expressions are induced by adding an inducer, so that the maximum expression quantity of the xanthine oxidase is realized.

The invention provides application of a roxburgh rose extract in preparation of a product for treating hyperuricemia and regulation and control of a purine metabolic pathway, and belongs to the technical field of biological medicines. The roxburgh rose aqueous extract extracted from roxburgh rose pomace can effectively intervene in hyperuricemia through a dual action mechanism: on one hand, the roxburgh rose aqueous extract significantly inhibits the expression of xanthine oxidase (XOD) in the liver, and reduces the generation of uric acid; on the other hand, expression of key urate transporters (including GLUT9, URAT1, ABCG2 and OAT1) is regulated and controlled, uric acid is promoted to be excreted through the kidney, and therefore the blood uric acid level is reduced in a synergistic mode, a solid theoretical basis and technical support are provided for developing a new HUA prevention and treatment strategy based on natural products, and a new thought is provided for prevention and treatment of hyperuricemia.

The invention relates to lactobacillus reuteri SAU-R-8 which is derived from Tibet naturally-fermented sour yak milk and is used for producing exopolysaccharides and application of the lactobacillus reuteri SAU-R-8 in reducing uric acid, and belongs to the technical field of microorganisms. The strain is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.30373, and the preservation date is April 19, 2024. The lactobacillus reuteri SAU-R-8 provided by the invention is screened from yak yogurt naturally fermented from herdsmen in the Sankarst region of Tibet, the yield of exopolysaccharides in an MRS culture medium reaches 318.57 mg / L, nucleoside substances such as inosine and guanosine can be efficiently degraded, purine substances such as guanine can be efficiently absorbed, the activity of xanthine oxidase can be inhibited, and the lactobacillus reuteri SAU-R-8 can be used for preparing the yak yogurt. The method can be further applied to product development for relieving or treating hyperuricemia.

The invention relates to the technical field of marine microorganisms, in particular to application of combined lactobacillus salivarius in preparation of products for improving metabolism of alcohol and uric acid, the combined lactobacillus salivarius NHNK-603 is preserved in the China Center for Type Culture Collection, and the preservation number is CCTCC NO: M 2024416. Experiments show; the NHNK-603 has the effects of inhibiting the growth of klebsiella pneumoniae, inhibiting the production of alcohol, agglutinating the klebsiella pneumoniae, inhibiting the virulence gene of the klebsiella pneumoniae, promoting alcohol metabolism, reducing alcohol damage, tolerating alcohol, degrading uric acid, inhibiting the activity of xanthine oxidase, promoting uric acid excretion, promoting the proliferation of Alistipes indinctus and synthesizing hippuric acid; the thallus biofilm increases the function of colonization on mucoprotein and intestinal epithelial cells, and can be applied to preparation of products for improving metabolism of alcohol and uric acid.

The invention provides a composition for reducing uric acid and relieving gout and a preparation method thereof, and relates to the technical field of products for reducing uric acid and relieving gout. The composition comprises the following raw materials: 18-24 parts of phellinus igniarius, 9-13 parts of sunflower disc small molecule peptide extract, 3-7 parts of corn stigma, 4-6 parts of poria cocos, 2-5 parts of pawpaw, 3-6 parts of liquorice, 2-5 parts of astragalus extract and 3-6 parts of lettuce extract. The preparation method of the sunflower disc small-molecule peptide extract comprises the following steps: carrying out enzymolysis on sunflower disc powder twice, carrying out membrane filtration to obtain a sunflower disc small-molecule peptide solution, reacting the sunflower disc small-molecule peptide solution with chitosan oligosaccharide and transglutaminase, and carrying out freeze drying to obtain the sunflower disc small-molecule peptide extract. Through the proper raw material composition and proportion, the metabolic function can be effectively regulated to promote excretion of uric acid, so that the content of xanthine oxidase and adenosine deaminase in the liver is obviously reduced, the uric acid level is effectively reduced, the intestinal probiotic structure can be stabilized, the immunity is enhanced, the kidney is protected, and the good effects of reducing uric acid and relieving gout are achieved.

The invention discloses application of benzofuran components in eupatorium chinense to reduction of uric acid, compounds 1-3 are obtained by being separated from an eupatorium chinense extract, and the compound 1 is a new compound. The eupatorium chinense root extract is separated by using an extraction method, macroporous adsorption resin impurity removal, HW-40F gel column chromatography, high performance liquid chromatography and other methods to obtain the benzofuran compound. According to the present invention, the inhibition activity of the gout disease related target xanthine oxidase of the separated compound 1-3 is tested, the experimental result shows that the compound 1-3 has good inhibition activity on the xanthine oxidase, and the molecular docking experiment shows that the compound 1-3 has good binding energy with the target protein. Therefore, the compounds 1-3 can be used for preparing a natural lead compound for delaying or treating diseases caused by xanthine oxidase and providing a natural lead compound in the field of treatment of hyperuricemia and gout.

The invention discloses a natural product composition and application thereof in reducing uric acid and blood sugar. The composition is prepared from luteolin, verbascoside and curcumin according to the weight ratio of 1: 3: 2. According to the invention, when luteolin, verbascoside and curcumin are combined according to a weight ratio of 1: 3: 2, the inhibitory activity on xanthine oxidase (XO) and alpha-glycosidase is the strongest, and the inhibitory activity is obviously superior to the inhibitory activity on xanthine oxidase (XO) and alpha-glycosidase when the luteolin, verbascoside and curcumin are independently used, so that the composition has a synergistic effect on reducing the level of uric acid and regulating blood sugar. The discovery provides a theoretical basis and a formula basis for developing novel natural-source functional products for reducing uric acid and reducing blood sugar, and has important application prospects and development values.

The present application relates to the preparation and application field of biological peptide, and more particularly to a hippocampus abdominalis peptide and its application in preparation of products for reducing uric acid and resisting gout. The amino acid sequence is shown as SEQ ID NO. 1, and the present application confirms the uric acid reducing effect through in vitro xanthine oxidase (XOD) and adenosine deaminase (ADA) inhibition experiments and cell experiments; on this basis, the uric acid reducing and gout resisting activity of the peptide sequence is further verified by means of a high uric acid animal model. This achievement provides a solid theoretical support for high-value development and utilization of hippocampus abdominalis, and research and development of products for reducing uric acid and resisting gout.

The invention discloses uric acid-reducing peptide goat milk powder and a preparation method thereof, and belongs to the technical field of enzymes. According to the process for preparing the uric acid lowering peptide by hydrolyzing goat milk through the compound enzyme, the total addition amount of the compound enzyme (the enzyme activity ratio of neutral protease N to neutral protease X is 1: 1) is 4000 U / g-6000 U / g, enzymolysis is conducted for 2-3 h at the temperature of 45-55 DEG C, and under the condition, the xanthine oxidase inhibition rate is 71.67 + / -1.32%-83.64 + / -0.98%. The enzymolysis goat milk containing the uric acid-reducing peptide is subjected to spray drying to prepare the uric acid-reducing peptide goat milk powder, and the storage stability of the goat milk powder is relatively good. The amino acid sequence and the source of the uric acid lowering peptide are separated and identified, the in-vitro uric acid lowering activity of the uric acid lowering peptide is verified through the solid-phase synthesized uric acid lowering peptide, and a theoretical basis and technical support are provided for development of new uric acid lowering peptide goat milk products.

This invention discloses a benzofuran compound and its application in lowering uric acid activity. Compounds 1-3 were isolated from the fermentation products of the endophytic fungus *Septoriella phragmitis*, with compound 1 being a novel compound. The fermentation products were purified using mixed solvent extraction, normal silica gel column chromatography, and high-performance liquid chromatography to obtain compounds 1-3. The inhibitory activity of compounds 1-3 on xanthine oxidase, a target related to gout symptoms, was tested. Experimental results showed that the novel compound 1 exhibited good inhibitory activity against xanthine oxidase. Molecular docking experiments also demonstrated that compound 1 had a good binding energy to the target protein. Therefore, compound 1 can be used to prepare a natural lead compound for delaying or treating diseases caused by xanthine oxidase, providing a potential therapeutic agent for hyperuricemia and gout.

The invention discloses phthalide compounds as well as a preparation method and application thereof. The phthalide compounds comprise a compound 1 and a compound 2 as well as a preparation method and application thereof. The two compounds are separated and purified from the ethyl acetate extract of the traditional Chinese medicine ligusticum wallichii for the first time. An in-vitro biological activity test shows that the two compounds have obvious inhibitory activity on xanthine oxidase, which indicates that the two compounds can be used as novel potential candidate drugs for treating hyperuricemia and gout. The embodiment of the invention provides a preparation method, structural identification and pharmacological action of the two phthalide compounds, and provides a new strategy for treatment of hyperuricemia and gout diseases.

The invention belongs to the field of gout prevention and treatment, and particularly relates to alpinia oxyphylla and turmeric tabletted sweets as well as a preparation method and application thereof. According to the alpinia oxyphylla and turmeric composition disclosed by the invention, alpinia oxyphylla and turmeric are taken as main components, the beautiful millettia root, the poria cocos, the kudzuvine root, the lithocarpus litseifolius, the purslane, the cassia seed, the black pepper and the dandelion are reasonably combined, and all the components are synergistically interacted, so that the prepared composition can remarkably improve the xanthine oxidase inhibition activity, can effectively relieve gout symptoms, and can be used for treating gout. The composition can be used for adjuvant therapy of gout patients. The tablet candy prepared by adding a sweetening agent into the alpinia oxyphylla turmeric composition disclosed by the invention is simple in preparation process, can be eaten for a long time as an auxiliary food in a gout treatment process, and has a great promoting effect on relieving gout symptoms.